Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term ambrisentan extension study in pediatric pulmonary arterial hypertension
RBR-7jcvv4Phase 2Recruiting
- Sponsor
- GSK
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ambrisentan in pulmonary arterial hypertension (PAH) (2 arms), sponsored by GSK. Started Jun 2011; status: recruiting.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on RBR-7jcvv4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-7jcvv4.